Cargando…

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents

We previously demonstrated the efficacy of the COVID-19 vaccine candidate, SCB-2019, in adults in the SPECTRA phase 2/3 efficacy study. We extended the study to include 1278 healthy 12–17-year-old adolescents in Belgium, Colombia, and the Philippines who received either two doses of SCB-2019 or plac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez, Pio, Bravo, Lulu, Buntinx, Erik, Borja-Tabora, Charissa, Velasquez, Hector, Rodriquez, Edith Johana, Rodriguez, Camilo A., Carlos, Josefina, Montellano, May Emmeline B., Alberto, Edison R., Salvani-Bautista, Milagros, Huang, Yung, Hu, Branda, Li, Ping, Han, Htay Htay, Baccarini, Carmen, Smolenov, Igor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronavirus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294745/ https://www.ncbi.nlm.nih.gov/pubmed/37226504 http://dx.doi.org/10.1080/21645515.2023.2206359

Ejemplares similares

Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study
por: Buntinx, Erik, et al.
Publicado: (2023)

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
por: Bravo, Lulu, et al.
Publicado: (2022)

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
por: Richmond, Peter, et al.
Publicado: (2021)

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial
por: Smolenov, Igor, et al.
Publicado: (2022)

Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
por: Ambrosino, Donna, et al.
Publicado: (2021)

Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study
por: Hosain, Romana, et al.
Publicado: (2023)

A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variants
por: Gao, Feixia, et al.
Publicado: (2023)

The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2
por: Li, Jing-Xin, et al.
Publicado: (2022)

Questionable robustness in the findings of a meta-analysis
por: Somovilla Del Saz, Borja
Publicado: (2023)

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
por: Roa, Camilo C, et al.
Publicado: (2023)

Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2
por: Chen, Na, et al.
Publicado: (2022)

Whole-Genome Sequences of the Archetypal K1 Escherichia coli Neonatal Isolate RS218 and Contemporary Neonatal Bacteremia Clinical Isolates SCB11, SCB12, and SCB15
por: Day, Michael W., et al.
Publicado: (2015)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

ScbR- and ScbR2-mediated signal transduction networks coordinate complex physiological responses in Streptomyces coelicolor
por: Li, Xiao, et al.
Publicado: (2015)

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
por: Xu, Shiqi, et al.
Publicado: (2022)

Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age
por: Bravo, Lulu C., et al.
Publicado: (2020)

Corrigendum: ScbR- and ScbR2-mediated signal transduction networks coordinate complex physiological responses in Streptomyces coelicolor
por: Li, Xiao, et al.
Publicado: (2016)

COVID-19 vaccine demand protest might have increased vaccine acceptance and uptake in South Africa
por: Mavundza, Edison Johannes, et al.
Publicado: (2022)

Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study
por: Costa Clemens, Sue Ann, et al.
Publicado: (2022)

The interplay between emerging human coronavirus infections and autophagy
por: Zhao, Zhenyu, et al.
Publicado: (2021)

Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials
por: Criscuolo, Elena, et al.
Publicado: (2021)

COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue
por: Yongzhi, Xi
Publicado: (2021)

Isolation of SARS-CoV-2 strains carrying a nucleotide mutation, leading to a stop codon in the ORF 6 protein
por: Delbue, Serena, et al.
Publicado: (2021)

Saliva viral load better correlates with clinical and immunological profiles in children with coronavirus disease 2019
por: Chua, Gilbert T., et al.
Publicado: (2021)

Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection
por: Ye, Zi-Wei, et al.
Publicado: (2021)

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
por: Hu, Yanmei, et al.
Publicado: (2021)

Novel dual multiplex real-time RT-PCR assays for the rapid detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus using the BD MAX open system
por: Chung, Hsing-Yi, et al.
Publicado: (2021)

Susceptibility of rabbits to SARS-CoV-2
por: Mykytyn, Anna Z., et al.
Publicado: (2021)

Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
por: Kim, Young-Il, et al.
Publicado: (2021)

A household case evidences shorter shedding of SARS-CoV-2 in naturally infected cats compared to their human owners
por: Neira, Víctor, et al.
Publicado: (2021)

A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques
por: Li, Yuzhong, et al.
Publicado: (2021)

Enhanced replication fitness of MERS-CoV clade B over clade A strains in camelids explains the dominance of clade B strains in the Arabian Peninsula
por: Te, Nigeer, et al.
Publicado: (2021)

Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
por: Brustolin, Marco, et al.
Publicado: (2021)

Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in the upper respiratory tract
por: Essaidi-Laziosi, Manel, et al.
Publicado: (2022)

Direct neuronal infection of SARS-CoV-2 reveals cellular and molecular pathology of chemosensory impairment of COVID-19 patients
por: Lyoo, Kwang-Soo, et al.
Publicado: (2022)

Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques
por: Xu, Fang, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
por: Wang, Yingdan, et al.
Publicado: (2022)

A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination
por: Du, Jinwei, et al.
Publicado: (2022)

Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants
por: Fan, Shengtao, et al.
Publicado: (2022)

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
por: Ai, Jingwen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3jqo0q9nnveink901hs6ktle0s